Similar expression profiles in CD34(+) cells from chronic phase chronic myeloid leukemia patients with and without deep molecular responses to nilotinib

The life expectancy of patients with chronic phase chronic myeloid leukemia on tyrosine kinase inhibitor therapy now approaches that of the general population. Approximately 60% of patients treated with second generation tyrosine kinase inhibitors achieve a deep molecular response, the prerequisite...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Patel, Ami B., Lange, Thoralf, Pomicter, Anthony D., Conley, Christopher J., Harrington, Christina A., Reynolds, Kimberly R., Kelley, Todd W., O’Hare, Thomas, Deininger, Michael W.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2018
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5915162/
https://ncbi.nlm.nih.gov/pubmed/29707154
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24954
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars